ライフサイエンスコーパス: cilengitide

1 ned clinical subgroups showed a benefit from cilengitide.

2 For patients treated at cilengitide 2,400 mg/m(2), the 6-month cumulative incide

3 receive temozolomide chemoradiotherapy with cilengitide 2000 mg intravenously twice weekly (cilengit

4 ality RIT (CMRIT) using RIT and six doses of Cilengitide (250 microg/dose; n = 41).

5 Cilengitide alone did not alter tumor growth when compar

6 Cilengitide also reduced the integrity of a brain endoth

7 Integrin beta3 antagonist, cilengitide, also enhanced tumor growth and increased M2

8 t other integrin subunits, or treatment with cilengitide, an Arg-Gly-Asp (RGD) mimetic, impaired HSV-

9 Cilengitide, an inhibitor of alphavbeta3 and alphavbeta5

10 Cilengitide, an inhibitor of specific integrins, rescues

11 ll migration and proliferation compared with cilengitide, an integrin-targeting peptidomimetic that p

12 In conclusion, CMRIT, combining Cilengitide and RIT, significantly increased the efficac

13 o, we show that coadministration of low-dose Cilengitide and Verapamil increases tumor angiogenesis,

14 Cilengitide (CGT) is a cyclic pentapeptide that demonstr

15 We aimed to assess cilengitide combined with temozolomide chemoradiotherapy

16 ning was performed on the cyclic RGD-peptide Cilengitide, cyclo[R-G-D-f-N(Me)V] 1, and its parent pep

17 etermine the maximum-tolerated dose (MTD) of cilengitide (EMD 121974) and to evaluate the use of perf

18 phase I trial of the antiangiogenesis agent cilengitide (EMD 121974), an alpha v beta 3,5 integrin a

19 her, and how, the cyclic Arg-Gly-Asp peptide Cilengitide (EMD 121974), which targets the alpha(v)beta

20 al was 26.3 months (95% CI 23.8-28.8) in the cilengitide group and 26.3 months (23.9-34.7) in the con

21 population were lymphopenia (31 [12%] in the cilengitide group vs 26 [10%] in the control group), thr

22 engitide 2000 mg intravenously twice weekly (cilengitide group) or temozolomide chemoradiotherapy alo

23 The phase II dosage of intravenous cilengitide in children with refractory brain tumors is

24 ucted to evaluate the activity and safety of cilengitide in GBM patients at first recurrence.

25 We observed that administration of cilengitide in nonresponder strains significantly rescue

26 ase 3 study, we investigated the efficacy of cilengitide in patients from 146 study sites in 25 count

27 Thus, the dual action of low-dose Cilengitide, in vessels and tumor cells, improves chemot

28 compared with untreated mice, but CMRIT with Cilengitide increased efficacy of treatment, with the cu

29 an alpha(v)beta(3) integrin-blocking mAb or cilengitide inhibited adherence and invasion by staphylo

30 Additional studies integrating cilengitide into combinatorial regimens for GBM are warr

31 Cilengitide is a selective alphavbeta3 and alphavbeta5 i

32 Cilengitide is well tolerated to doses of 2,400 mg/m2, d

33 Cilengitide (L2) or L1 provoked minor transient changes

34 imaging system, we report that a new (125)I-Cilengitide-like RGD-cyclopentapeptide, containing d-mor

35 Cilengitide monotherapy is well tolerated and exhibits m

36 moter, and 545 were randomly assigned to the cilengitide (n=272) or control groups (n=273) between Oc

37 n antibody as well as the inhibitory peptide cilengitide on BBB disruption during exposure to CMH (8%

38 ay 21, began a 2-week treatment with SC-080, cilengitide, or the EGFR inhibitor PKI166.

39 soluble RGD ligands, such as osteopontin or cilengitide, promoted association of Rab-coupling protei

40 s pathway, including the integrin antagonist cilengitide, providing a targeted therapeutic strategy f

41 alphavbeta3 signaling with a small molecule, cilengitide, rescued postinjury renal function in Col5a1

42 in clinical and preclinical use (SC-080 and cilengitide, respectively) mediates SMC apoptosis and re

43 Lower-dose RIT (200 mu Ci) combined with Cilengitide resulted in less increase in cures (36 compa

44 However, following cilengitide's unexpected clinical failure by promoting a

45 stin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Trea

46 ed Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Trea

47 A phase II trial to assess the efficacy of cilengitide therapy for children with refractory brain t

48 The addition of cilengitide to temozolomide chemoradiotherapy did not im

49 No vehicle- or cilengitide-treated animal survived beyond 2 weeks.

50 d between groups of untreated mice (n = 24), Cilengitide-treated mice (n = 18), RIT (200-260 mu Ci (9

51 ted no overall additional toxic effects with cilengitide treatment.

52 ssigned to receive either 500 or 2,000 mg of cilengitide twice weekly on a continuous basis.

53 Patients received cilengitide twice weekly on a continuous basis.

54 The safety profile of cilengitide was excellent, with no significant reproduci

55 zolomide was given for up to six cycles, and cilengitide was given for up to 18 months or until disea

56 tor capmatinib and/or the integrin inhibitor cilengitide was more effective than single-agent treatme

57 No increased toxicity attributable to Cilengitide was observed based upon pooled blood sample

58 the RGD sequence of the cyclic pentapeptide cilengitide when bound to integrin alpha(V)beta(3).

59 chemoradiotherapy did not improve outcomes; cilengitide will not be further developed as an anticanc